Aiforia Technologies

2.06 EUR

+12.94 %

2,197 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

+12.94 %
+21.18 %
-8.44 %
-17.27 %
-19.53 %
-42.78 %
-47.18 %
-
-59.29 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
69.6M EUR
Turnover
241.09K EUR
P/E (adj.) (26e)
-8.32
EV/EBIT (adj.) (26e)
-8.6
P/B (26e)
5.14
EV/S (26e)
15.37
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
2026-03-08
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2026-03-09

Latest extensive report

Released: 2025-04-24

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/5
2026

Extraordinary general meeting '26

28/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
In itself, I’m not sure if it would matter to a large player whether the situation is a few million in losses or a few million in profit, as long as the direction is clear. I suppose they are primarily buying an AI model that can be integrated into their own product to ensure the...
yesterday
by JusaVaan
12
At the extraordinary general meeting (EGM) on Tuesday, May 12, the board will be authorized to carry out a share issue of a maximum of 5 million shares. At the current share price, the subscription price would likely be around €1.7–1.8 per share, and the total number of shares would...
22 hours ago
by Jekkku
6
In fact, if consolidation is already well underway (referring to those LinkedIn posts as well), and Aiforia is among the few leaders / perhaps even the most convincing of those not yet acquired, why couldn’t an acquisition happen much sooner than I anticipated? Are there any milestones...
yesterday
by JusaVaan
6
Well, the shareholder base itself is partly problematic here, as they blocked a share issue that was essential for the growth story.
19 hours ago
by Puutaheinää
5
Some big fish will surely buy this at some point, but probably not just yet, as insiders have only recently been buying. In my opinion, it would also be better to develop the company further and get more references and AI models → better valuation. I’d also rather keep this on the...
20 hours ago
by Jekkku
4
I don’t think there’s a huge rush quite yet; there’s a new clinical model coming out by the summer, for instance, and perhaps new customer agreements as well. It might be worth holding off on the offering for a moment.
yesterday
by Puutaheinää
4
Based on the calculations I’ve been browsing through, they had €9m in cash in December. This should be enough until the autumn, but they won’t let it run completely dry. I would bet on a share issue still happening during H1.
yesterday
by Jekkku
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.